**Perioperative antithrombotic management in joint replacement surgeries**

**Objectives**
To determine optimal perioperative antithrombotic management for patients with cardiac diseases undergoing joint replacement surgeries.

**Data sources**
MEDLINE and PubMed database search up to January 2013.

**Study selection**
Those dealing with perioperative antithrombotic management of patients undergoing orthopaedic operations, especially joint replacement, and also those undergoing general surgery. Various combinations of the following key words were used in our search: “antiplatelet”, “antithrombotic”, “anticoagulant”, “coronary stent”, “perioperative”, “venous thromboembolism”, “cardiovascular”, “surgery”, “orthopaedic”, “knee replacement”, “hip replacement”, “joint replacement”, and “arthroplasty”.

**Data extraction**
Literature review, original articles, and best practice guidelines.

**Data synthesis**
Patients should be stratified according to their risk of developing arterial thromboembolism in order to decide the most appropriate perioperative antiplatelet or anticoagulant regimen for them. After recent coronary stenting, including bare-metal stents implanted within 6 weeks and drug-eluting stents implanted within 6 months, surgery should be deferred. For venous thromboembolism prophylaxis in patients already on aspirin, the dosage should be adjusted as necessary or additional low-molecular-weight heparin administered.

**Conclusion**
The perioperative management of patients with cardiac diseases in receipt of antithrombotic agents is based upon a delicate balance between the perceived risk of arterial thromboembolism and the perceived risk of perioperative bleeding. One must exercise good judgement in deciding the most appropriate perioperative antithrombotic regimen. Venous thromboembolism is also a common problem after joint replacement surgeries. For patients already on aspirin, optimal venous thromboembolism prophylaxis is still being debated.

**Introduction**
Joint replacement surgeries are a cost-effective measure to treat end-stage arthritis.\(^1\) Nowadays, it is common for patients with cardiac diseases on antithrombotic therapy to undergo joint replacement surgeries. This is partly due to the ageing population and increasingly sedentary lifestyle of most patients. Moreover, obesity itself is a common risk factor for the development of both coronary heart disease and degenerative arthritis.\(^2\)

In Queen Mary Hospital, during the period from January 2012 to December 2012, a total of 324 patients underwent elective primary total knee or total hip replacement surgeries. Among these patients, 52 (16%) were on some form of antithrombotic treatment. Of these 52 patients, 46 (88%) were on aspirin, two (4%) on warfarin, one (2%) on clopidogrel, one (2%) on low-molecular-weight heparin (LMWH), and two (4%) on dual antiplatelet therapy.

These patients pose a perioperative management dilemma to orthopaedic surgeons. On the one hand, there is concern about the increased risk of perioperative bleeding associated with continuing antithrombotic therapy.\(^3\) On the other hand, there is concern about the risk of arterial thromboembolism (ATE) that may manifest as an acute coronary syndrome (ACS) and/or stroke due to discontinuing these agents.\(^4\)

Venous thromboembolism (VTE) is also a common problem after joint replacement
surgeries and various prophylactic measures have been recommended. Many of these patients are already on aspirin for cardiac diseases and what constitutes optimal VTE prophylaxis strategy for this group of patients is still being debated.

We therefore set out to evaluate what might be optimal perioperative antithrombotic management for patients undergoing joint replacement surgeries. We also asked what could be the optimal strategy for the prevention of VTE in patients who are already on aspirin for the primary or secondary prevention of cardiac diseases.

Search strategy and criteria

We searched and reviewed the existing literature relevant to our questions using the MEDLINE and PubMed online database up to January 2013. Various combinations of the following keywords were used in our search: “antiplatelet”, “antithrombotic”, “anticoagulant”, “coronary stent”, “perioperative”, “venous thromboembolism”, “cardiovascular”, “surgery”, “orthopaedic”, “knee replacement”, “hip replacement”, “joint replacement”, and “arthroplasty”.

Patients on aspirin monotherapy

Aspirin is an antiplatelet and non-steroidal anti-inflammatory agent that works by inhibiting the synthesis of thromboxane A2, a potent stimulator of platelet aggregation by blocking the enzyme cyclooxygenase. It is widely used for primary and secondary prevention of ATE. Primary prevention is the implementation of certain interventions to prevent a healthy person from developing an illness, while secondary prevention refers to such measures to prevent progression or recurrence of a condition in a person already diagnosed to have had it.

Studies have shown that aspirin increases the risk of perioperative bleeding, but this does not translate into increased morbidity and mortality. A meta-analysis of 474 studies including orthopaedic and non-orthopaedic surgeries found that the risk of perioperative bleeding was 1.5 times higher in patients on low-dose aspirin (intake of less than 300 mg per day), but there was no significant difference in bleeding-related morbidity or mortality rates.

In two studies of patients on low-dose aspirin therapy undergoing proximal femoral fracture surgeries, patients on low-dose aspirin were shown to have an increased likelihood of receiving blood transfusions postoperatively, yet there was no increase in bleeding perioperatively (as measured by haemoglobin decrease or perioperative blood loss). The Pulmonary Embolism Prevention (PEP) trial, a randomised study involving 17,444 patients undergoing hip fracture surgeries and elective joint replacement surgeries who had low-dose aspirin started preoperatively for VTE prophylaxis, showed no difference in bleeding-related deaths between the low-dose aspirin and placebo groups. However, the frequency of bleeding treated with blood transfusions was 0.6% higher in the low-dose aspirin group.

On the other hand, the risk of discontinuing aspirin perioperatively is well documented. Abrupt discontinuation of aspirin is believed to produce rebound prothrombotic activity. A meta-analysis of 50,279 patients taking low-dose aspirin for secondary prevention showed that the risk of ATE after aspirin withdrawal was 3-fold higher than in those who continued taking it.

These studies suggest that discontinuing
aspirin therapy should only be considered if the risk of bleeding in a particular patient outweighs that of ATE, and therefore it seems sensible to stratify patients according to their risk profile.

Indeed, in the recent 2012 guidelines published by the American College of Chest Physicians (ACCP), it is recommended that patients be stratified according to their risk of ATE.11 For high-risk patients, such as those taking aspirin for secondary prevention of ATE, it is recommended that it should be continued perioperatively. For low-risk patients, such as those taking aspirin for primary prevention of ATE, stopping aspirin 7 to 10 days before surgery is recommended,72 this being the time needed to replenish the entire platelet pool.13,14 For the latter group of patients, it was also recommended that they resume aspirin within 24 hours of surgery as soon as haemostasis is achieved.

In its guidelines on prevention of VTE for patients, the American Academy of Orthopaedic Surgeons recommended discontinuing antiplatelet therapy prior to undergoing elective hip and knee replacement surgeries.53 These recommendations were mainly based on studies showing higher postoperative blood loss and higher reoperation rates in patients undergoing coronary artery bypass grafting (CABG) surgeries. However, the guidelines did not weigh these against the risk of ATE after stopping antiplatelet therapy. It is probably more practical to follow the ACCP guidelines regarding perioperative antiplatelet therapy and stratify patients according to their ATE risks.

**Patients on clopidogrel monotherapy**

Clopidogrel is another type of antiplatelet agent that works by antagonising ADP receptors on platelet cell membranes, thus blocking ADP-mediated platelet aggregation. It is now commonly used as an alternative to aspirin in the primary and secondary prevention of ATE. Comparing the risk of bleeding in those on high-dose aspirin and clopidogrel, the CAPRIE trial8 (involving 19 185 patients randomised to clopidogrel 75 mg once daily and aspirin 325 mg once daily) found that gastro-intestinal haemorrhage occurred in 2% of the clopidogrel group, and 2.7% of those on aspirin. Intracranial haemorrhage occurred in 0.4% of the clopidogrel group, and 0.5% of the aspirin group.86 To date, there are no such large-scale comparisons for low-dose aspirin versus clopidogrel.

A few studies have examined the perioperative bleeding risk of patients on clopidogrel monotherapy. One study involving patients undergoing transbronchial lung biopsy showed a higher rate of bleeding in the clopidogrel-only group (89%) compared with the controls (3.4%), but there were no adverse clinical outcomes as all the bleeding could be controlled endoscopically. It was recommended that clopidogrel should be stopped before transbronchial biopsy.77 Two studies involving fracture surgeries both showed no differences in the rate of bleeding complications in patients on clopidogrel and in those who were not.88,89 These results show that continuation of clopidogrel during the perioperative period may be safe in some orthopaedic surgeries.

The European Association of Cardiothoracic Surgery has published guidelines on the perioperative management of patients on clopidogrel who are about to undergo urgent cardiac surgery. The guidelines recommended stopping clopidogrel 5 to 7 days before surgery. Currently, however, there are no guidelines on clopidogrel use perioperatively for non-cardiac surgery.

More objective evidence is clearly needed to determine optimal perioperative management of patients receiving clopidogrel. Given the limited evidence currently available, it is probably sensible to stratify patients according to their risk of ATE (as for those on aspirin therapy), and then determine whether to continue or discontinue clopidogrel perioperatively.

**Patients on dual antiplatelet therapy**

Nowadays, it is common for patients to receive dual antiplatelet therapy with aspirin and clopidogrel. In particular, benefits of such dual therapy have been demonstrated in patients with an ACS, and those undergoing an elective percutaneous coronary intervention (PCI).20 Dual antiplatelet therapy is generally considered to confer a higher risk of bleeding than single antiplatelet therapy. The CURE study showed that patients who are on dual antiplatelet therapy had a 1% higher rate of bleeding complications than those on aspirin monotherapy (3.7% vs 2.7%), irrespective of whether they underwent surgery.21 Most of the data regarding perioperative bleeding with dual antiplatelet therapy were derived from patients undergoing CABG surgeries. In these studies, it was shown that dual antiplatelet therapy increased the risk of postoperative blood loss and receipt of blood transfusions following CABG, but there were no significant differences in terms of surgical mortality or outcomes.22-24 One study showed that patients on dual antiplatelet therapy who underwent vascular, orthopaedic, and visceral surgical procedures had a higher chance of receiving a blood transfusion than controls on monotherapy (43% vs 39%).25 These studies suggest that dual antiplatelet therapy in the perioperative period increases postoperative bleeding rates, but does not influence postoperative morbidity or mortality.

The ACCP guidelines recommend continuing aspirin and discontinuing clopidogrel 5 days before CABG.91 However, there are no up-to-date guidelines
for patients undergoing non-cardiac surgery. Patients receiving dual antiplatelet therapy usually have a history of ACS and a high risk of ATE; the risks of stopping both antiplatelet agents or even clopidogrel alone should be carefully balanced against the risks of perioperative bleeding. Close liaison with a cardiologist could be beneficial in devising the most suitable perioperative drug management plan for such patients.

Patients having coronary artery stenting

Coronary artery stenting is now common in patients undergoing PCIs, as it has a higher success rate and lower restenosis rate than angioplasty alone.26

There are two main types of stents that are commonly used, namely: the bare-metal stent (BMS) and the drug-eluting stent (DES). The BMS was introduced in the early 1990s and was used after PCIs to prevent collapse of the coronary artery following balloon angioplasty. Stent placement causes endothelial damage of the coronary artery, the damaged tissues eventually undergo re-endothelialisation, which takes approximately 3 months.27 Frequently there is excessive re-endothelialisation following BMS implantation, which leads to a high in-stent re-stenosis rate. Such restenosis after BMS implantation manifests as recurrent angina and warrants repeat revascularisation in 10 to 30% of patients.28 To address this issue, in the late 1990s the DES was devised. This stent is capable of preventing neointimal proliferation by releasing antiproliferative agents.29 This has decreased the need for target lesion revascularisation by as much as 75%.29 The downside is that it also delays the re-endothelialisation process and thus lengthens the time of exposed stent struts, which act as a potent nidus for stent thrombosis.30

Stent thrombosis is a platelet-mediated process on exposed stent struts that lead to progressive platelet activation, aggregation, and eventually thrombus formation. Both BMS and DES are prone to stent thrombosis prior to re-endothelialisation of the coronary arteries, which usually occurs within the first month.31 Thus, in the vast majority of cases dual antiplatelet therapy is prescribed early after stenting to prevent stent thrombosis during the vulnerable period. Late (1 month to 1 year after stenting) and very-late (more than 1 year after stenting) stent thrombosis is more common with DES use due to delayed re-endothelialisation and/or premature discontinuation of antiplatelet therapy.32,33 Furthermore, the prothrombotic and proinflammatory effects of surgery may predispose the coronary circulation to thrombosis, both at the site of stent placement and at other atherosclerotic lesions.34,35 Thus, there is a high risk of perioperative complications following withdrawal of antiplatelet therapy in patients with recently implanted stents, with studies showing that in these patients the mean perioperative mortality rates are as high as 20 to 40%.36-38 It has therefore been recommended that patients with recently implanted stents should continue dual antiplatelet therapy in the immediate perioperative period.

Furthermore, the ACCP has also recommended deferring elective surgery for at least 6 weeks after placement of a BMS and at least 6 months after placement of DES. In patients requiring urgent surgery within this time frame, the guidelines recommend that dual antiplatelet therapy should be continued perioperatively.39 The American Heart Association has also published guidelines in 2007 recommending deferment of elective surgery until at least 4 to 6 weeks after placement of a BMS and at least 12 months after placement of a DES.40 If procedures involving high risk of bleeding that mandate discontinuing clopidogrel must be performed within this time frame, the guidelines suggest that it is reasonable to discontinue clopidogrel 5 to 7 days preoperatively and restart the drug as soon as possible postoperatively.

Newer anticoagulants such as heparin do not decrease the risk of stent thrombosis and therefore should not be considered as substitutes for antiplatelet therapy. Again, it is recommended that the best perioperative management regimen for this group of at-risk patients should be discussed with a cardiologist.

Patients on anticoagulant therapy

Indications for chronic anticoagulation of patients with cardiac diseases include atrial fibrillation and the presence of mechanical heart valves. Warfarin is the most commonly used oral agent for these patients. Newer drugs such as dabigatran (Pradaxa; Boehringer Ingelheim, Germany), rivaroxaban (Xarelto; Bayer, Leverkusen, Germany), and apixaban (Eliquis; Pfizer and Bristol-Myers Squibb, New York, US) have also been introduced into the market and have been licensed for use in patients with atrial fibrillation.

Multiple studies have shown that interruption of warfarin therapy is necessary to minimise perioperative bleeding.41-43 It has been shown that most surgical procedures can be performed safely if the international normalised ratio (INR) is less than 1.5.44 It has also been reported that if the INR is between 2 and 3 on warfarin, it almost always falls to less than 1.5 within 4.8 days of the last dose.45 Therefore, ACCP guidelines recommend stopping warfarin 5 days before surgery and resuming therapy 12 to 24 hours after surgery provided there
is adequate haemostasis. Newer anticoagulants such as dabigatran, rivaroxaban, and apixaban have shorter half-lives than warfarin, and therefore it is recommended to stop these agents 1 to 4 days before undergoing surgery; for patients taking dabigatran, the duration varies depending on renal function.

Bridging therapy is the administration of heparin while warfarin is discontinued. It is used commonly during the perioperative period, since heparin has a short duration of action and its activity is readily reversible. Nowadays, bridging therapy is mainly resorted to with LMWH and only very infrequently with intravenous unfractionated heparin. The advantages of LMWH include ease of administration and the fact that it requires no monitoring, provided the patient does not have renal failure and is not pregnant.

Guidelines published by the ACCP recommend that patients on warfarin should be stratified according to their risk of developing ATE. Risk stratification for chronic atrial fibrillation is based on the CHADS2 score, while that for mechanical heart valves is based on the position and type of valve (Table 1). Patients are divided into low-, moderate-, and high-risk groups. In the low-risk group, no bridging therapy is recommended after stopping warfarin. Contrarily, in high-risk patients, bridging is always recommended after stopping warfarin. For the moderate-risk group, the decision is based on the individual patient- and surgery-related risk factors. The guidelines also recommend administering the last preoperative LMWH dose 24 hours before surgery and for non–high-bleeding-risk surgeries (including joint replacements) resume treatment in the first 24 hours after surgery.

In the setting of total knee replacement surgeries, the conventional perioperative practice of discontinuing warfarin with or without switching to bridging therapy has recently been challenged. Concerns have been raised that bridging therapy results in rebound hypercoagulability after warfarin withdrawal, and that there are large fluctuations in INR when switching back to warfarin. Thus, recently there have been studies to examine whether it is safe to continue warfarin perioperatively without recourse to bridging. One retrospective study showed no increase in bleeding complications of patients who continued regular dosing of warfarin perioperatively, when compared with subjects who discontinued warfarin and switched to bridging therapy. Likewise, another recent retrospective study showed no increase in bleeding complications in patients who continued regular dosing with warfarin perioperatively, when compared with those not on warfarin therapy. Larger-scale studies are needed to justify such a change from conventional practice. Moreover, the rapid offset and onset of newer anticoagulants may obviate the need for bridging therapy. Nonetheless, more studies are needed to determine optimal perioperative management for patients taking newer drugs.

Venous thromboembolism prophylaxis for patients with cardiac disease who are already on aspirin

It is well known that patients undergoing joint replacement surgeries are at risk of developing VTE postoperatively. Many of these patients have concomitant cardiac diseases and may already be on aspirin. The optimal VTE prophylaxis for these patients is still under debate.

The PEP trial enrolled 17,444 patients undergoing either total knee or hip joint replacement surgeries or hip fracture surgeries in the mid-1990s. The results showed that compared with patients assigned to placebo, those randomised to low-dose aspirin (160 mg once daily taken for up to 35 days post-surgery) had a 28% relative risk reduction in symptomatic deep venous thrombosis (DVT), but there was no demonstrable benefit from aspirin with respect to non-fatal pulmonary embolism (PE). The pooled results of two studies comparing LMWH against aspirin in VTE prophylaxis yielded more asymptomatic DVT in the aspirin group, with an odds

---

**Table 1. Guidelines published by the American College of Chest Physicians suggest risk stratification for perioperative thromboembolism**

<table>
<thead>
<tr>
<th>Risk stratum</th>
<th>Mechanical heart valve</th>
<th>Indication for warfarin therapy</th>
<th>Atrial fibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Any mitral valve prosthesis</td>
<td>CHADS&lt;sup&gt;2&lt;/sup&gt; score of 5 or 6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any caged-ball or tilting disc aortic valve prosthesis</td>
<td>Recent (&lt;3 months) stroke or transient ischaemic attack</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recent (&lt;6 months) stroke or transient ischaemic attack</td>
<td>Rheumatic valvular heart disease</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>Bileaflet aortic valve prosthesis and one or more of the following risk factors: atrial fibrillation, prior stroke or transient ischaemic attack, hypertension, diabetes, congestive heart failure, age &gt;75 years</td>
<td>CHADS&lt;sup&gt;2&lt;/sup&gt; score of 3 or 4</td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>Bileaflet aortic valve prosthesis without atrial fibrillation and no other risk factors for stroke</td>
<td>CHADS&lt;sup&gt;2&lt;/sup&gt; score of 0 to 2 (assuming no prior stroke or transient ischaemic attack)</td>
<td></td>
</tr>
</tbody>
</table>

* CHADS<sub>2</sub> = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus (1 point for each), and stroke or transient ischaemic attack (2 points); total 6 points maximum
ratio of 1.9, but there were too few patients with PE for meaningful comparison. These data suggest that aspirin is a feasible option for VTE prophylaxis, but overall evidence points to LMWH as the preferred treatment.

Recently, the ACCP has published its ninth edition guidelines for VTE prophylaxis, specifically for patients undergoing orthopaedic surgery, in which both low-dose aspirin and LMWH were listed as options. It was also suggested that LMWH should be preferred over other medications including aspirin for prophylaxis of VTE, regardless of whether an intermittent pneumatic device was offered as mechanical prophylaxis. One of the authors of a review article also suggested that patients already on aspirin should have LMWH added for prophylaxis of VTE. In the American Academy of Orthopaedic Surgeons guidelines, it was suggested that pharmacological agents and/or mechanical compressive devices should be used for the prevention of VTE. However, these did not provide guidance on the appropriate pharmacological agents of choice.

Based on the ACCP guidelines, LMWH should be started 12 hours or more before surgery or 12 hours or more after surgery at a prophylactic dose for at least 10 to 14 days after surgery. It was also suggested that VTE prophylaxis be extended into out-patient attendance (35 days after surgery). We therefore recommend that patients who are already on low-dose aspirin increase the dosage to at least 160 mg daily postoperatively until 35 days post-surgery and then resume the usual dosage. Alternatively, in addition to the usual aspirin treatment, prophylactic LMWH should be started 12 hours or more preoperatively, or 12 hours or more postoperatively and continued up to 10 to 14 days post-surgery and

### TABLE 2. An algorithm for perioperative drug management of patients with cardiac diseases

<table>
<thead>
<tr>
<th>Patients on the following drugs</th>
<th>Risk stratification</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>Low</td>
<td>Stop aspirin 7-10 days before surgery, resume aspirin postoperatively as soon as haemostasis achieved</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>Continue aspirin perioperatively</td>
</tr>
<tr>
<td>Need VTE prophylaxis</td>
<td>Usual dosage &lt;160 mg daily:</td>
<td>(i) increase dosage to 160 mg daily postoperatively up to 35 days post-surgery then resume usual dosage; or (ii) add LMWH in addition for 10-14 days after surgery, then switch to aspirin 160 mg daily up to 35 days after surgery before resuming usual dosage of aspirin</td>
</tr>
<tr>
<td></td>
<td>Usual dosage ≥160 mg daily:</td>
<td>(i) continue usual dosage of aspirin; or (ii) add LMWH in addition to usual dosage of aspirin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Additional use of IPCD for mechanical prophylaxis of VTE postoperatively recommended for all cases</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>Low</td>
<td>Stop clopidogrel 5-7 days before surgery, resume treatment postoperatively as soon as haemostasis achieved</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>Continue clopidogrel postoperatively</td>
</tr>
<tr>
<td>Dual antiplatelet</td>
<td>Usually high</td>
<td>Consult cardiologist</td>
</tr>
<tr>
<td>Recent coronary stent implantation</td>
<td>BMS</td>
<td>Consult cardiologist</td>
</tr>
<tr>
<td></td>
<td>DES</td>
<td>Consult cardiologist</td>
</tr>
<tr>
<td></td>
<td>BMS/DES + urgent surgery required</td>
<td>Consult cardiologist</td>
</tr>
<tr>
<td>Anticoagulant therapy</td>
<td>Low</td>
<td>Stop warfarin 5 days before surgery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No bridging therapy required</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Resume warfarin postoperatively as soon as haemostasis achieved</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>Stop warfarin 5 days before surgery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Need for bridging therapy should be based on individualised assessment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consult cardiologist if in doubt</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>Stop warfarin 5 days before surgery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Switch to bridging heparin therapy when the INR falls below the therapeutic range</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Restart warfarin post-surgery as soon as haemostasis is achieved</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discontinue bridging heparin therapy when the INR is in the therapeutic range</td>
</tr>
</tbody>
</table>

* BMS denotes bare-metal stent, DES drug-eluting stent, INR international normalised ratio, IPCD intermittent pneumatic compression device, LMWH low-molecular-weight heparin, and VTE venous thromboembolism
then switch to aspirin 160 mg daily till 35 days postsurgery before resuming the usual dosage.

**Discussion**

The perioperative management of patients with cardiac diseases on antiplatelet or anticoagulant therapy undergoing joint replacement surgeries is based on a delicate balance between the perceived risk of ATE and/or VTE and the perceived risk of perioperative bleeding. Table 2 summarises the perioperative drug management approach to this group of patients. Patients should be stratified according to their risk of developing ATE to select the most appropriate perioperative antplatelet or anticoagulant regimen. For low-risk patients, it is recommended that antplatelet therapy and anticoagulant therapy be discontinued before surgery and resumed as soon as possible thereafter, provided there is adequate haemostasis. For high-risk patients, antplatelet therapy should be continued; bridging therapy should be considered for those on anticoagulants. Elective joint replacement surgeries should be deferred for patients who have had recent implantation of coronary stents in receipt of dual antiplatelet therapy. For VTE prophylaxis, during the postoperative period these patients can receive either an adjusted aspirin dosage or LMWH in addition to their usual aspirin dosage.

For these patients, close liaison with a cardiologist is essential in order to devise the most appropriate perioperative drug regimen, especially for those whose ATE risk may be difficult to determine.

**Declaration**

No conflicts of interest were declared by authors.

**References**


30. Alfonso F. The "vulnerable" stent why so dreadful? J Am Coll Cardiol 2008;51:2403-6. crossref
42. McKenna R. Abnormal coagulation in the postoperative period contributing to excessive bleeding. Med Clin North Am 2001;85:1277-130, viii. crossref